Bioventix plc
("Bioventix" or the "Company")
Director dealing
Bioventix plc (AIM: BVXP) was notified on 16 April 2015 that on the same day,
due to institutional investor demand, the following director dealt in the
ordinary shares of 5 pence each ("Ordinary Shares") in the Company:
Name Position Type of Number of Price Ordinary Percentage
transaction Ordinary per shares and of Ordinary
Shares Ordinary voting Shares and
Share rights held voting
(pence) following rights held
the following
transaction the
transaction
Peter Chief Disposal 100,000* 800 661,176 13.1%
Harrison Executive
* 3,000 of which were held in the name of his wife
For further information please contact:
Bioventix plc Chief Executive Officer Tel: 01252 728 001
Peter Harrison
finnCap Ltd Corporate Finance Tel: 020 7220 0500
Geoff Nash/Simon Hicks Corporate Broking
Steve Norcross
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.© 2015 PR Newswire
